drugset / Trial / NCT06972888

A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis

NCT06972888

Phase 2 Completed 145 enrolled Accro Bioscience (Suzhou) Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of AC-201 tablets compared with placebo in subjects with moderate-to-severe plaque psoriasis

Timeline

Start
2024-04-23
Primary completion
2025-03-07
Completion
2025-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Diacerein Small molecule Oral

Indications